Neustar International Security Council launched ... » LONDON, UK: Neustar, Inc. has announced the launch of the Neustar International Security Council (NI... RiskIQ Digital Threat Management Platform Recognis... » LONDON, UK: RiskIQ has been recognised in an Ovum Research “On the Radar” report for providing orga... ExtraHop introduces new professional services fo... » UK: Today at Interop ITX has announced new professional services for cloud migration, datacenter mig... MIKE SMITH BECOMES NEW ECA PRESIDENT » A highly respected electrical engineer and businessperson – Mike Smith of SES Engineering Services –... Patriot One obtains purchase agreement with rese... » TORONTO:  Patriot One Technologies Inc. has announced a reseller agreement with Information Technolo... TDSi and LITESTAR announce new partnership in Si... » Poole: TDSi has announced a new partnership with Singapore-based installation specialist LITESTAR Te... FSA 10TH BIRTHDAY TOPS THE BILL AT IFSEC SHOW » Fire and security business representatives are being urged to attend the Fire & Security Association... Intercede announces Secure Login for WordPres... » Lutterworth, England/Reston, VA: Recently, digital identity and credentials expert, Intercede announ... Senior Intelligence Official Ron Moultrie joi... » NEW YORK, NY: Balabit has announced today that the former Director of Operations at the National Sec... Luke Kleszcz joins security manufacturer as Fina... » Poole: Integrated has announced the growth of its Finance team with the appointment of its new Finan...

CLICK HERE TO

SOCIAL BOOKMARK

Health Security Header

LONDON, UK: The UK Department of Health’s rejection of an 800,000-signature public petition to expand the routine administration of the only approved vaccine to offer protection against invasive meningococcal disease (IMD) caused by serogroup B (MenB), may lead to parents and physicians to consider purchasing the vaccine themselves, according to an analyst with research and consulting firm GlobalData.

The decision to keep free access to GlaxoSmithKline’s MenB vaccine, Bexsero, limited to infants rather than vaccinating children up to 11 years of age, as requested in the petition, is a significant setback for the advocacy groups and parents aiming for expanded vaccine administration.

Mirco Junker, Ph.D., GlobalData’s Analyst covering Infectious Diseases, explains: “Even though IMD cases caused by serogroups B and C are most prevalent, the majority of European countries only routinely administer meningococcal vaccines against serogroup C, which provide excellent safety and efficacy profiles in combination with relatively low price points. MenB vaccines, on the other hand, are relatively new and expensive, and there is only limited clinical data demonstrating their long-term effectiveness.

“This uncertainty regarding the long-term efficacy - together with studies indicating low cost-effectiveness of MenB vaccines - also highlights the general conflicts rare diseases like IMD bring up when medical needs are pitted against the commercial viability of vaccines. Indeed, vaccinating entire populations against rare diseases can be extremely challenging to rationalize from a pharmacoeconomic perspective.”

In fact, in 2014, a study using the analysis of quality-adjusted life-years indicated that the new MenB vaccine would not be cost-effective even if provided to the National Health Service (NHS) for less than £1 per dose. However, cost-effectiveness should not be viewed as the main determining factor for the broad application of a vaccine against a rare disease, as many vaccines might not pass this threshold, given low enough disease prevalence.

Junker continues: “While the Department of Health’s decision is a disappointment for parents worried about their children developing IMD, GlobalData believes it is understandable from the perspective of the NHS, as healthcare costs continue to rise and governmental agencies have to balance the restraints of a limited budget with society’s medical needs.

“A reasonable compromise could be to provide individual families concerned about IMD to purchase vaccines out-of-pocket without having to face the list price of the vaccine. As such, it might be in the interest of the pharmaceutical industry to provide incentives to make the vaccine available to individuals not covered under the NHS guidelines.”